

## New Fused Quinoxalines : Synthesis and Reactions of Pyrimidothienoquinoxaline and Oxadizolythienoquinoxalines

Osama S. Moustafa,\* Mahmoud Z. A. Badr, and Talaat I. El-Emary

Chemistry Department, Faculty of Science, Assiut University, Assiut 71516, Egypt

Received November 22, 2001

Diazotization of 3-amino-2-ethoxycarbonylthieno[2,3-b]quinoxaline **1** gave the diazonium salt **2** which was reacted with SO<sub>2</sub> and *N*-methylaniline to give sulfamoylquinoxaline derivatives **3-5**. Imidazothienoquinoxaline **8** was obtained from the reaction of carboxylic acid hydrazide **6** with nitrous acid and followed by boiling the carbozide **7** in dry xylene. Also, compound **6** react with CH(OEt)<sub>3</sub> to give aminopyrimidine **9** which was reacted with arylidene malonodinitrile, furfural and/or dimethoxy-tetrahydrofuran to afford compounds **10, 11** and/or **12** respectively. Refluxing of **6** with CS<sub>2</sub> gave oxadiazolylthienoquinoxaline **13**, reaction of **13** with hyrazine hydrate, CH(OEt)<sub>3</sub>, nitrous acid, CS<sub>2</sub> and  $\alpha$ -halocompounds to give **14-19**.

**Keywords** : Synthesis, Diazotization, Heterocycles, Pyrimidothienoquinoxalines.

### Introduction

Among the wide variety of quinoxaline derivatives that have been explored for developing pharmaceutically important molecules for examples, imidazoquinoxalines ribonucleosides as linear of antiviral,<sup>1</sup> pyrazoloquinoxaline showed a relatively high antibacterial activity wherien MIC value was 25  $\mu$ g/mL against *Bacillus Licheniformis* and *Cellulomonas* Sp.,<sup>2</sup> quinoxaline-1,4-di-*N*-oxides for treatment of tuberculosis,<sup>3</sup> pyrimido[4,5-b]quinoxaline used as anti-hypertensive and blood platelet antiaggregating agents,<sup>4</sup> also some quinoxaline derivatives have a cytotoxic effects on human cancer cell lines,<sup>5,6</sup> commercially impotant as agrochemicals,<sup>7</sup> herbicides,<sup>8</sup> hypoxic-cytotoxic agents,<sup>9</sup> antiviral (Hepatitis B),<sup>10</sup> antimicrobial,<sup>11</sup> and amebicides,<sup>12</sup> we are taking all the above benefits into consideration and in continuation of our work in synthesis of fused heterocyclic rings with quinoxaline moiety.<sup>13-19</sup>


### Results and Discussion

In this work we aimed to synthesize some diferent hetero-

cycles systems fused with thieno[2,3-b]quinoxaline hoping that they may be highly biological activity. The reaction of 3-amino-2-ethoxycarbonylthieno[2,3-b]quinoxaline **1**<sup>15</sup> with nitrous acid and then sulfur dioxide and cupric chloride in acetic acid gave the 2-ethoxycarbonylthieno[2,3-b]quinoxaline-3-sulfonylchloride **3** via the diazonium salt **2**.<sup>15</sup> The reaction of **3** with *N*-methylaniline afforded the 3-sulfamoylthienoquinoxaline **4**, whose hydrolysis provided the 3-sulfamoyl-2-carboxylic acid **5** (Scheme 1).


3-Amino-2-thieno[2,3-b]quinoxaline-2-carboxylic acid hydrazide **6** was obtained by refluxing the coressponding ethyl ester **1** in ethanolic hydrazine hydrate<sup>14</sup> which was reacted with nitrous acid (NaNO<sub>2</sub>/AcOH) to produce the corresponding 3-amino-2-carbozide derivative **7**, which underwent Curtius rearrngment when refluxed in dry xylene to the imidazothieno[2,3-b]quinoxalinone **8** (Scheme 2).

The reaction of carohydrazide **6** with triethyl orthoformate in ethanol in the presence of catalytic amount of acetic acid led to the formation of 3-aminopyrimidothieno[2,3-b]quinoxalinone **9**, which was subjected to Michael reaction when reacted with benzylidene malonodinitrile in ethanol in the presence of a few drops of piperidine to give the pyrida-




Scheme 1

\*Corresponding Author: E-mail: oshmous@aun.eun.eg



Scheme 2



Scheme 3


zinopyrimidothieno[2,3-b]quinoxalinone **10**. While the reaction of aminopyrimidine **9** with furfural and with dimethoxytetrahydrofuran provided the Schiff bases **11** and 3-(1-pyrrolyl) derivative **12**, respectively (Scheme 3).

When the carbonylhydrazone **6** was refluxed with carbon disulfide in pyridine gave oxadiazolylthienoquinoxaline **13** which was refluxed with hydrazine hydrate to produce 3-amino-2-(2-hydrazino-1,3,4-oxadiazol-5-yl)thieno[2,3-b]quinoxaline **14**. The latter compound was reacted with triethyl orthoformate and with nitrous acid to give (triazolo and tetrazolo)oxadiazolylthienoquinoxalines **15** and **16** respectively. Also, when **14** was allowed to react with carbon disulfide in pyridine the sulfanyltriazolooxadiazolyl derivative **17** was formed. Furthermore, the reaction of the thio-

oxadiazol **13** with  $\alpha$ -halocompounds in the presence of sodium acetate yield S-alkylated derivatives **18** and **19** (Scheme 4).

### Experimental Section

Melting points were determined on a Gallen Kamp melting point apparatus and were uncorrected. IR spectra were recorded on a Pye-Unicam SP<sup>3</sup>-100 spectrophotometer using KBr wafer technique. <sup>1</sup>H NMR spectra were recorded on a 90 MHz Varian EM-390 NMR spectrometer in a suitable deuterated solvent (TMS) as the internal standard. Elemental analyses were determined on a Perkin-Elmer 240 C micro-analyzer. Elemental analysis, melting points, yields and



Scheme 4

**Table 1.** Melting Points, Yields and Analytical Data of Compounds 3-19

| Comp. No       | M.P. <sup>o</sup> C (Yield%) | Formula Mol. Wt   | Calculated/found |      |       |       |
|----------------|------------------------------|---|------------------|------|-------|-------|
|                |                              |   | C                | H    | N     | S     |
| 3 <sup>a</sup> | 310 (80)                     | C <sub>13</sub> H <sub>9</sub> N <sub>2</sub> O <sub>4</sub> S <sub>2</sub> Cl<br>356.5 | 43.75            | 2.52 | 7.85  | 17.95 |
|                |                              |   | 43.67            | 2.41 | 7.79  | 17.89 |
| 4              | 180 (68)                     | C <sub>20</sub> H <sub>17</sub> N <sub>3</sub> O <sub>4</sub> S <sub>2</sub><br>427     | 56.20            | 3.98 | 9.83  | 14.98 |
|                |                              |   | 56.07            | 3.86 | 9.78  | 14.88 |
| 5              | 220-21 (75)                  | C <sub>18</sub> H <sub>13</sub> N <sub>3</sub> O <sub>4</sub> S <sub>2</sub><br>399     | 54.13            | 3.25 | 10.52 | 16.04 |
|                |                              |   | 54.17            | 3.20 | 10.43 | 15.89 |
| 7              | 240 (83)                     | C <sub>11</sub> H <sub>6</sub> N <sub>6</sub> OS<br>270                                 | 48.88            | 2.22 | 31.11 | 11.85 |
|                |                              |   | 48.79            | 2.18 | 31.07 | 11.78 |
| 8              | 190 (80)                     | C <sub>11</sub> H <sub>6</sub> N <sub>4</sub> OS<br>242                                 | 54.54            | 2.47 | 23.14 | 13.22 |
|                |                              |   | 54.49            | 2.38 | 23.09 | 13.11 |
| 9              | 290 (70)                     | C <sub>12</sub> H <sub>7</sub> N <sub>5</sub> OS<br>269                                 | 53.53            | 2.60 | 26.02 | 11.89 |
|                |                              |   | 53.44            | 2.56 | 26.12 | 11.90 |
| 10             | 225 (77)                     | C <sub>22</sub> H <sub>11</sub> N <sub>7</sub> OS<br>421                                | 62.70            | 2.61 | 23.27 | 7.60  |
|                |                              |   | 62.61            | 2.54 | 23.00 | 7.54  |
| 11             | >360 (70)                    | C <sub>17</sub> H <sub>9</sub> N <sub>5</sub> O <sub>2</sub> S<br>347                   | 58.78            | 2.59 | 20.17 | 9.22  |
|                |                              |   | 58.67            | 2.44 | 20.12 | 9.13  |
| 12             | 115 (90)                     | C <sub>16</sub> H <sub>9</sub> N <sub>5</sub> OS<br>319                                 | 60.18            | 2.82 | 21.94 | 10.03 |
|                |                              |   | 59.98            | 2.77 | 21.84 | 10.00 |
| 13             | 320 (81)                     | C <sub>12</sub> H <sub>7</sub> N <sub>5</sub> OS <sub>2</sub><br>301                    | 47.84            | 2.32 | 23.25 | 21.26 |
|                |                              |   | 47.76            | 2.23 | 23.14 | 21.19 |
| 14             | 260 (82)                     | C <sub>12</sub> H <sub>9</sub> N <sub>7</sub> OS<br>299                                 | 48.16            | 3.01 | 32.77 | 10.70 |
|                |                              |   | 48.29            | 3.10 | 33.00 | 10.68 |
| 15             | >360 (75)                    | C <sub>13</sub> H <sub>7</sub> N <sub>7</sub> OS<br>309                                 | 50.48            | 2.26 | 31.71 | 10.35 |
|                |                              |   | 50.30            | 2.22 | 31.61 | 10.27 |
| 16             | >360 (69)                    | C <sub>12</sub> H <sub>6</sub> N <sub>8</sub> OS<br>310                                 | 46.45            | 1.93 | 36.12 | 10.32 |
|                |                              |   | 46.50            | 1.90 | 36.21 | 10.36 |
| 17             | 120 (90)                     | C <sub>13</sub> H <sub>7</sub> N <sub>7</sub> OS <sub>2</sub><br>341                    | 45.74            | 2.05 | 28.73 | 18.76 |
|                |                              |   | 45.61            | 2.00 | 28.66 | 18.59 |
| 18             | 150 (78)                     | C <sub>13</sub> H <sub>9</sub> N <sub>5</sub> OS <sub>2</sub><br>315                    | 49.52            | 2.85 | 22.22 | 20.31 |
|                |                              |   | 49.60            | 2.86 | 22.16 | 20.22 |
| 19             | 240 (83)                     | C <sub>16</sub> H <sub>13</sub> N <sub>5</sub> O <sub>3</sub> S <sub>2</sub><br>387     | 49.61            | 3.35 | 18.08 | 16.53 |
|                |                              |   | 49.44            | 3.32 | 18.00 | 16.41 |

<sup>a</sup>Cl (calc. 9.95, found 9.88%).

spectroscopic data of compounds 3-19 are listed in Tables 1 and 2.

**3-Amino-2-ethoxycarbonylthieno[2,3-b]quinoxaline (1) 2-Ethoxycarbonylthieno[2,3-b]quinoxaline-3-diazonium chloride (2).** Compounds 1 and 2 were prepared according to the literature, mp 145 and 258 °C, respectively; Lit [15].

**2-Ethoxycarbonylthieno[2,3-b]quinoxaline-3-sulfonylchloride (3).** To a solution of compound 2 (0.01 mol) in glacial acetic acid (30 mL) was added cupric chloride (0.015 mol), a slow rate of SO<sub>2</sub> was passed through this solution for 1 hr, stand the reaction mixture for 2 h at RT and the mixture was poured into water. The solid separated was filtered and crystallized from acetic acid as greenish crystals.

**Ethyl 3-(N-methyl-N-phenyl)sulfamoylthieno[2,3-b]quinoxaline-2-carboxylate (4).** A mixture of 3 (0.01 mol) and N-methylaniline (0.01 mol) in absolute ethanol was refluxed for 3 h, after cooling. The solid product thus formed was recrystallized from ethanol as red crystals.

**3-(N-Methyl-N-phenyl)sulfamoylthieno[2,3-b]quinoxaline-2-carboxylic acid (5).** A sample of 4 (0.5 g) in 10% KOH (25 mL) was heated under reflux for 2 h, then allowed to cool, neutralized with dilute HCl. The solid product thus formed was recrystallized from ethanol as red crystals.

**3-Amino-2-thieno[2,3-b]quinoxaline-2-carboxylic acid hydrazide (6).** Compound 6 was prepared according to the literature m.p. 305-306 °C; Lit [14].

**3-Amino-2-thieno[2,3-b]quinoxaline-2-carboazide (7).** To a mixture of 6 (0.01 mol) and acetic acid (15 mL) was added sodium nitrite solution (14 mL, 0.01 mol) at 0° with stirring for 30 min and the resulting solid was filtered and recrystallized from ethanol as yellow crystals.

**Imidazo[4',5':4,5]thieno[2,3-b]quinoxalin-2(1H, 3H)-one (8).** A sample of 7 (0.5 g) in dry xylene (15 mL) was heated under reflux for 30 min, then allowed to cool. The solid product thus formed was recrystallized from ethanol as yellow crystals.

**Table 2.** Spectroscopic Data of Compounds 3-19

| Compound No. | IR (ν cm <sup>-1</sup> ) / <sup>1</sup> H NMR δ (ppm)  |
|--------------|--|
| 3            | 1720 (CO), 1620 (C=N); (DMSO-d <sub>6</sub> ): δ 1.3-1.45 (t, 3H, CH <sub>3</sub> ) 4.2-4.4 (q, 2H, CH <sub>2</sub> ), 7.3-7.8 (m, 4H, Ar-H).  |
| 4            | 1730 (CO), 1610 (C=N); (DMSO-d <sub>6</sub> ): δ 1.3-1.4 (t, 3H, CH <sub>3</sub> ), 3.2 (s, 3H, CH <sub>3</sub> ), 4.2-4.4 (q, 2H, CH <sub>2</sub> ), 7.4-7.9 (m, 9H, Ar-H).                                 |
| 5            | 1740 (CO), 1630 (C=N); (CF <sub>3</sub> COOD): δ 3.2 (s, 3H, CH <sub>3</sub> ), 7.4-8.1 (m, 9H, Ar-H).   |
| 7            | 3380 (NH <sub>2</sub> ), 2180 (N <sub>3</sub> ), 1730 (N <sub>3</sub> -CO); (DMSO-d <sub>6</sub> ): δ 6.2 (s, 2H, NH <sub>2</sub> ), 7.5-8.0 (m, 4H, Ar-H).  |
| 8            | 3210, 3185 (NH), 1670 (CO); (CDCl <sub>3</sub> ): δ 7.5-8.3 (m, 4H, Ar-H), 9.2, 10.3 (s, 2H, NH).  |
| 9            | 3340 (NH <sub>2</sub> ), 1680 (C=O); (DMSO-d <sub>6</sub> ): δ 6.3 (s, 2H, NH <sub>2</sub> ), 7.5-7.8 (m, 4H, Ar-H), 9.5 (s, 1H, CH).  |
| 10           | 3420 (NH <sub>2</sub> ), 2220 (CN), 1700 (C=O); (DMSO-d <sub>6</sub> ): δ 6.2 (s, 2H, NH <sub>2</sub> ), 7.4-7.9 (m, 9H, Ar-H).  |
| 11           | 2960 (CH, aliph.), 1690 (CO), 1620 (C=N).  |
| 12           | 1700 (CO) 1640 (C=N); (DMSO-d <sub>6</sub> ): δ 6.1, 6.3 (2d, 4H, CH-pyrrole), 7.6-8.2 (m, 4H, Ar-H), 9.4 (s, 1H, CH).   |
| 13           | 3430 (NH <sub>2</sub> ), 1230, 1060 (SH); (DMSO-d <sub>6</sub> ): δ 6.24 (s, 2H, NH <sub>2</sub> ), 7.5-8.2 (m, 4H, Ar-H).   |
| 14           | 3220, 3500 (NH, NH <sub>2</sub> ), 1630 (C=N); (CF <sub>3</sub> COOD): δ 7.5-7.95 (m, 4H, Ar-H).   |
| 15           | 3430 (NH <sub>2</sub> ); (DMSO-d <sub>6</sub> ): δ 6.15 (s, 2H, NH <sub>2</sub> ), 7.5-8.2 (m, 4H, Ar-H), 9.4 (s, 1H, CH).   |
| 16           | 3400 (NH <sub>2</sub> ), 1620 (C=N); (CF <sub>3</sub> COOD): δ 7.5-7.95 (m, 4H, Ar-H).   |
| 17           | 3400 (NH <sub>2</sub> ), 1220, 1050 (SH); (DMSO-d <sub>6</sub> ): δ 6.25 (s, 2H, NH <sub>2</sub> ), 7.45-8.0 (m, 4H, Ar-H).  |
| 18           | 3410 (NH <sub>2</sub> ); (CDCl <sub>3</sub> ): δ 3.3 (s, 3H, CH <sub>3</sub> ), 6.1 (s, 2H, NH <sub>2</sub> ) 7.6-8.2 (m, 4H, Ar-H)  |
| 19           | 3420 (NH <sub>2</sub> ), 2930 (CH, aliph.), 1720 (C=O); (CDCl <sub>3</sub> ): δ 1.4-1.6 (t, 3H, CH <sub>3</sub> ), 4.1-4.25 (q, 2H, CH <sub>2</sub> ), 6.2 (s, 2H, NH <sub>2</sub> ), 7.4-8.1 (m, 4H, Ar-H). |

**3-Amino-pyrimido[4',5':4,5]thieno[2,3-b]quinoxalin-4(2H)-one (9)**. To a mixture of **6** (0.015 mol) and triethyl orthoformate (5 mL) in methanol (30 mL), few drops of acetic acid were added. The mixture was heated under reflux for 5 h, then allowed to cool. The solid product thus formed was recrystallized from ethanol as red crystals.

**2-Amino-3-cyano-4-Phenylpyridazino[2'',3''':1',2']pyrimido[4',5':4,5]thieno[2,3-b]quinoxalin-13-one (10)**. A solution of **9** (0.01 mol), arylidene malonodinitrile (0.01 mol) in absolute ethanol (10 mL) and (1 mL) of triethylamine, was stirred at reflux for 2 h. After cooling the solid product was filtered, washed with cool ethanol and recrystallized from ethanol as pale yellow crystals.

**3-(2-Furfurilidene)aminopyrimido[4',5':4,5]thieno[2,3-b]quinoxalin-4(3H)-one (11)**. A solution of compound **9** (0.01 mol) and furfural (0.015 mol) in glacial acetic acid (40 mL) was heated at 80° for 4 h. After cooling the separated solid was filtered and crystallized from acetic acid as brownish crystals.

**3-(1-Pyrryl)pyrimido[4',5':4,5]thieno[2,3-b]quinoxalin-4(3H)-one (12)**. To a solution of compound **9** (0.01 mol) in glacial acetic acid (20 mL) was added dimethoxy-tetrahydrofuran (0.015 mol), and the mixture was refluxed, stirred for 2 h, evaporated under reduced pressure, the residue was crystallized from ethanol/acetic acid as redish crystals.

**3-Amino-2-(5-sulfanyl-1,3,4-oxadiazol-2-yl)thieno[2,3-b]quinoxaline (13)**. A mixture of **6** (0.01 mol) and carbon disulfide (5 mL) in pyridene (25 mL) was refluxed on steam bath for 8 h, then allowed to cool. The solid product thus formed was recrystallized from ethanol as red crystals.

**3-Amino-2-(5-hydrazino-1,3,4-oxadiazol-2-yl)thieno[2,3-b]quinoxaline (14)**. A mixture of **13** (0.01 mol) and hydrazine hydrate (6 mL) was refluxed in ethanol (35 mL) for (5 h, or until evolution of H<sub>2</sub>S cease) then allowed to cool, the yellow precipitate was filtered off and recrystallized from ethanol.

**3-Amino-2-(1,2,4-triazolo[3,4-b][1,3,4]oxadiazol-6-yl)thieno[2,3-b]quinoxaline (15)**. To a mixture of **14** (0.015 mol) and triethyl orthoformate (3 mL) in methanol (20 mL), few drops of acetic acid were added. The mixture was heated under reflux for 3 h, then allowed to cool. The solid product thus formed was recrystallized from acetic acid as pale red crystals.

**3-Amino-2-(tetrazolo[4,5-b][1,3,4]oxadiazol-6-yl)thieno[2,3-b]quinoxaline (16)**. To a solution of **14** (0.01 mol) in acetic acid (25 mL) was added dropwise sodium nitrite solution (14 mL, 0.01 mol) at 0° with stirring for 2 h. The resulting solid was filtered and recrystallized from ethanol as yellowish crystals.

**3-Amino-2-(3-sulfanyl-1,2,4-triazolo[3,4-b]oxadiazol-6-yl)thieno[2,3-b]quinoxaline (17)**. A mixture of **14** (0.01

mol) and carbon disulfide (5 mL) in pyridine (35 mL) was refluxed on steam bath for 6 h, then allowed to cool. The solid product thus formed was recrystallized from acetic acid as pale red crystals.

**3-Amino-2-(5-methylthio-1,3,4-oxadiazol-2-yl)thieno[2,3-b]quinoxaline (18)**. A mixture of **13** (0.01 mol), methyl iodide (0.01 mol) and anhydrous sodium acetate (5 g) in ethanol (40 mL) was refluxed for 2 h, poured onto cold water. The solid obtained was filtered off and recrystallized from ethanol as pale yellow crystals.

**3-Amino-2-(5-ethylacetatethio-1,3,4-oxadiazol-2-yl)thieno[2,3-b]quinoxaline (19)**. A mixture of **13** (0.01 mol), ethyl chloroacetate (0.01 mol) and anhydrous sodium acetate (5 g) in ethanol (30 mL) was refluxed for 2 h, poured onto cold water. The solid obtained was filtered off and recrystallized from ethanol as pale yellow crystals.

## References

- Zhu, Z.; Saluja, S.; Drach, C. J.; Townsend, L. P. *J. of the Chinese Chem. Soc.* **1988**, 45(4), 465.
- (a) Makino, K.; Kim, H. S.; Yoshihisa, K. *J. Heterocycl. Chem.* **1998**, 35, 321. (b) Makino, K.; Kim, H. S.; Yoshihisa, K. *J. Heterocycl. Chem.* **1998**, 35, 489.
- Sainz, Y.; Montoya, M. E.; Martinez, F. J.; Ortega, M. A.; Lopez, A.; Monge, A. *Arznie. Forsch.* **1999**, 49, 55. [*Chem. Abstr.* **1999**, 130, 3827P].
- Mange, A.; Palop, J. A.; Urbasos, I.; Fernandez-Alvarez, E. *J. Heterocycl. Chem.* **1989**, 26, 1623.
- Yoo, H. W.; Yun-Sil, L.; Suh, M. E.; Kim, D. J.; Park, S. W. *Arch. Pharm.* **1998**, 331, 10331.
- Gozyo, S.; Kenzi, M.; Yoshihisa, K. *Heterocycles* **1988**, 27, 2481.
- Kaneko, C.; Katagiri, S. (Asahi Glass Co.Ltd), Japan Kokai Tokkyo Koho Jp. (patent) **1988**, 62, 207, 264. [*Chem. Abstr.* **1988**, 109, 231061f].
- Hiramatsu, T.; Azuma, S.; Nakagawa, K.; Ichikawa, Y. (Teijin Ltd.) Japan Kokai Tokkyo Koho Jp. (patent), **1988**, 62, 163, 263. [*Chem. Abstr.* **1988**, 109, 73473k].
- Miguel, A. O.; Maria, J. M.; Francisco, J. M.; Yolanda, S.; Maria, E. M.; Adele, L. C.; Antonio, M. *Eur. J. Med. Chem. Chim. Ther.* **2000**, 35, 121.
- El-Ashry, E. S. H.; Abdel-Rahman, A. A. H.; Rashed, N.; Rasheed, H. A. *Pharmazie* **1999**, 54(12), 893.
- El-Hawash, S. A.; Habib, N. S.; Fanaki, N. H. *Pharmazie* **1999**, 54, 808.
- Bindumhavan, V.; Prabhakar, B. C.; Kumar, C. D.; John, D. N.; Helmut, R. R. (Hoechst India Ltd.) Indian IN 167,425 (patent) **1993**, [*Chem. Abstr.* **1993**, 119, 117279q].
- Moustafa, O. S. *Phosphorus, Sulfur and Silicon* **1997**, 131, 49.
- Badr, M. Z. A.; Mahgoub, S. A.; Moustafa, O. S. *J. Chem. Soc. Pakistan* **1993**, 15, 264.
- Badr, M. Z. A.; Mahgoub, S. A.; Moustafa, O. S. *Phosphorus, Sulfur and Silicon* **1993**, 79, 477.
- Moustafa, O. S. *Phosphorus, Sulfur and Silicon* **1999**, 155, 235.
- Moustafa, O. S. *J. of the Chinese Chem. Soc.* **2000**, 47(2), 351.
- Geies, A. A.; El-Deen, A. M. K.; Moustafa, O. S. *Pharmazie* **1996**, 52(6), 437.
- Moustafa, O. S.; Badr, M. Z. A.; Kamel, E. M. *Pharmazie* **2000**, 55(12), 896.